Real-world Insights: Physician-assessed and Patient-reported Outcomes in Atopic Dermatitis Patients Treated with Dupilumab

A recent update from the GLOBOSTAD study offered valuable insights into the real-world effectiveness of dupilumab, a promising treatment for atopic dermatitis (AD). The study, spanning over 5 years and conducted across multiple countries, aimed to evaluate the extended real-world effectiveness of dupilumab in patients with AD receiving it as part of their routine care.

The primary objective of this analysis was to report patient-reported outcomes and physician-assessed clinical measures of AD characteristics, severity, and treatment effectiveness 1 year after initiating dupilumab therapy.

Conducted as a multinational prospective observational study (registered as NCT03992417), the research enrolled patients aged 12 years and older with moderate-to-severe AD. Patients received dupilumab according to country-specific prescribing guidelines. Assessments were conducted at baseline, 3 months, 6 months, and 12 months post-treatment initiation.

The study included data from 955 patients for enrollment and safety evaluation, with 903 patients comprising the follow-up population. Notably, 13 adolescent patients aged 12 to 18 years with AD were also included.

Over the course of the 1-year observational period, significant improvements were observed in key AD outcome measures. The mean Eczema Area and Severity Index (EASI) scores decreased from 25.1 at baseline to 4.2 at 12 months, indicating a substantial reduction in disease severity. Similarly, the Patient-Oriented Eczema Measure showed consistent improvement over time, with notable decreases in both adult and adolescent patient populations.

Moreover, improvements in quality of life were evident, as reflected by reductions in Dermatology Life Quality Index (DLQI) scores, indicating a positive impact of dupilumab treatment on patients' overall well-being. Safety data remained consistent with previous findings, with dupilumab-related adverse events reported in 20.8% of patients

“In a real-world scenario, the initiation of dupilumab treatment led to early and sustained improvements in AD outcome measures throughout the 1-year observational period. Safety data remained consistent with findings from previous studies,” concluded the study authors.

Reference

Ferrucci SM, Calzavara-Pinton P, Murrell DF, Fougerousse A, Karlova I, et al. Physician-assessed effectiveness and patient-reported outcomes in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study. British Journal of Dermatology. Published online February 7, 2024. https://doi.org/10.1093/bjd/ljad498.036